Searchable abstracts of presentations at key conferences in endocrinology

ea0050oc4.3 | Adrenal and Steroids | SFEBES2017

Local reactivation of glucocorticoids by 11β-HSD1 mediates their detrimental effects on bone

Fenton Chloe , Doig Craig , Raza Karim , Cooper Mark , Lavery Gareth , Hardy Rowan

Glucocorticoids (GCs) have potent immunomodulatory and anti-inflammatory effects and are widely used in the treatment of inflammatory diseases. Unfortunately, their long term administration causes serious systemic metabolic side effects including osteoporosis, muscle wasting and insulin resistance. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is responsible for the local conversion of inactive GCs to their active counterparts. It has been shown that many of the...

ea0050oc5.5 | Reproduction and Neuroendocrinology | SFEBES2017

Vitamin-D and fetomaternal immunity: next generation RNA sequence analysis reveals unique effects upon uterine natural killer cells

Tamblyn Jennifer , Jeffery Louisa , Susarla Radhika , Knoblich Konstantin , Fletcher Anne , Kilby Mark , Hewison Martin

Vitamin D deficiency is prevalent in pregnant women and associated with adverse pregnancy outcomes, including pre-eclampsia. Active vitamin-D (1,25(OH)2D3) exerts important non-classical immune-regulatory effects, and the maternal placenta (decidua) appears a key target. Uterine natural killer cells (uNKs) are the most prominent decidual immune cell during early pregnancy. Given their critical role in fetal implantation and placentation, we hypothesised uNKs are a local source...

ea0050oc6.2 | Bone, Calcium and Neoplasia | SFEBES2017

Glucocorticoids activation by 11beta-hydroxysteroid dehydrogenase type 1 protects against inflammatory bone loss in a murine model of chronic inflammation

Hardy Rowan , Fenton Chloe , Begum Rumina , Naylor Amy , Saghir Atif , Lavery Gareth , Cooper Mark , Raza Karim

Local and systemic bone loss is a common complication in patients with chronic inflammatory disease. Previously, we have identified that glucocorticoid (GC) activation by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is increased within tissues such as bone during systemic inflammation. However, whilst effective at suppressing inflammation, in excess, GCs drive osteoporosis. To determine the contribution of 11β-HSD1 activated glucocorticoids to inf...

ea0050p202 | Diabetes and Cardiovascular | SFEBES2017

Selective expresssion of one specific isoform of the coxsackie adenovirus receptor (CAR) in the human pancreatic beta cells

Ifie Eseoghene , Russell Mark A , Sebastiani Guido , Dotta Francesco , Marjomaki Varpu , Morgan Noel G , Richardson Sarah J

Aims and Objective: A transmembrane cell-adhesion protein, the Coxsackie-adenovirus receptor (CAR) serves as an entry receptor for enteroviruses and may be essential for their ability to infect cells. Since beta-cell enteroviral infection could contribute to the development of Type 1 diabetes, it is important that CAR expression is analysed in the human pancreas. CAR exists as at least 5 isoforms and we have studied the expression of these dif...

ea0050p206 | Diabetes and Cardiovascular | SFEBES2017

The impact of a dedicated metabolic hepatology clinic for the treatment of non-alcoholic fatty liver disease

Motohashi Kenzo , Moolla Ahmad , Marjot Tom , Ainsworth Mark , Tomlinson Jeremy , Cobbold Jeremy

Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is tightly associated with insulin resistance and type 2 diabetes (T2DM), both risk factors for disease progression, liver failure and cardiovascular complications. A multidisciplinary approach involving hepatologists and diabetologists working alongside allied health professionals is thus advocated for the management of NAFLD. Interv...

ea0050p242 | Neoplasia, Cancer and Late Effects | SFEBES2017

Combination of JQ1, an inhibitor of epigenetic pathways, and everolimus for treatment of pancreatic and bronchial neuroendocrine tumours

Lines Kate E , Stevenson Mark , Filippakopoulos Panagis , Grozinsky-Glasberg Simona , Bountra Chas , Thakker Rajesh V

Current treatments, including surgery, medical therapy, radiotherapy, and radionuclide therapy for neuroendocrine tumours of the pancreas (PNETs) and bronchus (BNETs) are often unsatisfactory, leading to a 5-year survival of <50% and 5%, respectively. PNETs and BNETs frequently have mutations in chromatin-remodelling genes and the protein encoded by the multiple endocrine neoplasia type 1 (MEN1) gene, menin. Menin binds the...

ea0050p266 | Neuroendocrinology and Pituitary | SFEBES2017

Patterns of recurrence, response to treatment and mortality in patients with malignant phaeochromocytomas and paragangliomas. – a single centre experience

Abdel-Aziz Tarek , Chung Teng-Teng , Bomanji Jamshed , Gaze Mark , Kurzawinski Tom

Introduction: Histology is a poor predictor of the malignant potential of phaeochromocytomas and paragangliomas (PPGL) and only the presence of distant metastasis confirms malignancy. This study reviews patterns of recurrence, treatment and mortality in patients with malignant PPGL presenting to our department at UCLH over 30 years.Materials and Methods: In our series of 128 patients with PPGL, 26 (20%) with maligna...

ea0050p267 | Neuroendocrinology and Pituitary | SFEBES2017

11C-methionine PET can aid localisation of the source of ACTH-dependent Cushing’s syndrome in patients with equivocal or negative conventional imaging.

Tobin Jake , White Louisa , Koulouri Olympia , Bashari Waiel , Powlson Andrew , Gillett Daniel , Cheow Heok , Gurnell Mark

Background: Cross-sectional imaging (e.g. CT/MRI) can not always reliably identify the site of ACTH secretion in Cushing’s disease (CD) or the ectopic ACTH syndrome (EAS). We report our experience of localising the source of ACTH-dependent Cushing’s syndrome, using functional imaging with 11C-methionine positron emission tomography (Met-PET).Methods: Forty consecutive patients with: (i) de novo ...

ea0050p272 | Neuroendocrinology and Pituitary | SFEBES2017

The severity of obstructive sleep apnoea does not influence ambient IGF-I levels

Lynch Julie , Kyriakakis Nikolaos , Elliott Mark , Ghosh Dipansu , Nix Mitchell , Watts Sue , Murray Robert D

Introduction: Obstructive sleep apnoea (OSA) is reported to have effects on a number of hormone systems including glycaemic control, catecholamines, and the HPA axis. In this study we aimed to determine the impact of OSA on IGF-I levels.Patients & Methods: This is a prospective cohort study performed at Leeds Teaching Hospitals. Patients were recruited from the Sleep Apnoea Clinic between November 2014 and May 2...